Clinical Trials Logo

Renal Cell Carcinoma clinical trials

View clinical trials related to Renal Cell Carcinoma.

Filter by:

NCT ID: NCT04440943 Completed - Breast Cancer Clinical Trials

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Start date: August 4, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.

NCT ID: NCT04402749 Completed - Clinical trials for Renal Cell Carcinoma

The Incidence of Pulmonary Embolism During Nephrectomy

Start date: October 1, 2020
Phase:
Study type: Observational

Patients with renal carcinoma was reported at high incidence of perioperative pulmonary embolism from current study. The investigators aimed to determine the incidence and outcome of this group of patient in the tertiary-care, university hospital and the rate of intraoperative transesophageal echocardiography utility and outcome.

NCT ID: NCT04309617 Completed - Clinical trials for Renal Cell Carcinoma

Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy

Start date: July 31, 2019
Phase:
Study type: Observational

This study aims at estimating the proportion of patients diagnosed with locoregional renal cell carcinoma who are at high risk for recurrence following nephrectomy, describe referral patterns, and characterize treatment in this population. Outcomes including estimation of the incidence of recurrence and disease-free interval following nephrectomy will be reported overall and among the subgroup off patients receiving adjuvant systemic therapy with sunitinib following nephrectomy.

NCT ID: NCT04213157 Completed - Surgery Clinical Trials

Laparoscopic Partial Nephrectomy for cT1 Tumors

Start date: March 15, 2019
Phase:
Study type: Observational

The aim of the study is to evaluate trifecta and pentafecta outcomes for laparoscopic partial nephrectomy (LNP) in patients with clinical T1N0M0 renal tumor.

NCT ID: NCT04077359 Completed - Clinical trials for Renal Cell Carcinoma

Prospective Trial for Examining Hematuria Using Computed Tomography

PROTEHCT
Start date: September 15, 2019
Phase: N/A
Study type: Interventional

The primary objective is to evaluate whether one-phase nephrographic CT (experimental) is sufficient to detect urothelial cell carcinoma in patients with hematuria compared to the traditional four-phase CT (control).

NCT ID: NCT03894618 Completed - Melanoma Clinical Trials

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Start date: March 26, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.

NCT ID: NCT03849469 Completed - Clinical trials for Hepatocellular Carcinoma

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

DUET-4
Start date: May 29, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

NCT ID: NCT03841110 Completed - Colorectal Cancer Clinical Trials

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Start date: February 15, 2019
Phase: Phase 1
Study type: Interventional

FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.

NCT ID: NCT03829436 Completed - Colorectal Cancer Clinical Trials

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Start date: March 20, 2019
Phase: Phase 1
Study type: Interventional

This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1 antibody, in subjects with advanced solid tumors.

NCT ID: NCT03776123 Completed - Clinical trials for Hepatocellular Carcinoma

Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients

Start date: May 15, 2019
Phase:
Study type: Observational

The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling after the approval of marketing authorization.